Molecular Dynamics Simulations of the Adenosine A2a Receptor: Structural Stability, Sampling, and Convergence

Molecular dynamics (MD) simulations of membrane-embedded G-protein coupled receptors (GPCRs) have rapidly gained popularity among the molecular simulation community in recent years, a trend which has an obvious link to the tremendous pharmaceutical importance of this group of receptors and the increasing availability of crystal structures. In view of the widespread use of this technique, it is of fundamental importance to ensure the reliability and robustness of the methodologies so they yield valid results and enable sufficiently accurate predictions to be made. In this work, 200 ns simulations of the A2a adenosine receptor (A2a AR) have been produced and evaluated in the light of these requirements. The conformational dynamics of the target protein, as obtained from replicate simulations in both the presence and absence of an inverse agonist ligand (ZM241385), have been investigated and compared using principal component analysis (PCA). Results show that, on this time scale, convergence of the replicates is not readily evident and dependent on the types of the protein motions considered. Thus rates of inter- as opposed to intrahelical relaxation and sampling can be different. When studied individually, we find that helices III and IV have noticeably greater stability than helices I, II, V, VI, and VII in the apo form. The addition of the inverse agonist ligand greatly improves the stability of all helices.

[1]  David Rodríguez,et al.  Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. , 2011, Biochemistry.

[2]  B. Hess,et al.  Similarities between principal components of protein dynamics and random diffusion , 2000, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[3]  Marta Filizola,et al.  Dynamic models of G-protein coupled receptor dimers: indications of asymmetry in the rhodopsin dimer from molecular dynamics simulations in a POPC bilayer , 2006, J. Comput. Aided Mol. Des..

[4]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[5]  Albert C. Pan,et al.  Structure of the M3 Muscarinic Acetylcholine Receptor , 2012 .

[6]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[7]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[8]  Anat Levit,et al.  Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. , 2010, Current opinion in drug discovery & development.

[9]  Thomas Williams,et al.  Gnuplot 4.4: an interactive plotting program , 2010 .

[10]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[11]  Xiao-dan Li,et al.  Ligands stabilize specific GPCR conformations: but how? , 2012, Structure.

[12]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[13]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[14]  Ron O. Dror,et al.  High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar , 2012, Nature.

[15]  Maarten G. Wolf,et al.  g_membed: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation , 2010, J. Comput. Chem..

[16]  Alan Grossfield,et al.  Quantifying uncertainty and sampling quality in biomolecular simulations. , 2009, Annual reports in computational chemistry.

[17]  B. Hess Convergence of sampling in protein simulations. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[18]  R. Millar,et al.  Alanine-261 in intracellular loop III of the human gonadotropin-releasing hormone receptor is crucial for G-protein coupling and receptor internalization. , 1998, The Biochemical journal.

[19]  René Meier,et al.  Generation of a homology model of the human histamine H3 receptor for ligand docking and pharmacophore-based screening , 2007, J. Comput. Aided Mol. Des..

[20]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[21]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[22]  Laura López,et al.  Progress in the structural prediction of G protein‐coupled receptors: D3 receptor in complex with eticlopride , 2011, Proteins.

[23]  Thomas B Woolf,et al.  Molecular dynamics simulation of dark-adapted rhodopsin in an explicit membrane bilayer: coupling between local retinal and larger scale conformational change. , 2003, Journal of molecular biology.

[24]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[25]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[26]  E. Bastia,et al.  Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. , 2005, Pharmacology & therapeutics.

[27]  Alan Grossfield,et al.  Convergence of molecular dynamics simulations of membrane proteins , 2007, Proteins.

[28]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[29]  Stephen Neidle,et al.  Molecular dynamics and principal components analysis of human telomeric quadruplex multimers. , 2008, Biophysical journal.

[30]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[31]  J. Ballesteros,et al.  Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. , 2002, The Journal of biological chemistry.

[32]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[33]  Daniel M Zuckerman,et al.  On the structural convergence of biomolecular simulations by determination of the effective sample size. , 2007, The journal of physical chemistry. B.

[34]  N. Aiyar,et al.  G protein-coupled receptors in drug discovery. , 2003, Assay and drug development technologies.

[35]  Tod D Romo,et al.  Validating and improving elastic network models with molecular dynamics simulations , 2011, Proteins.

[36]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[37]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[38]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[39]  A. Ivanov,et al.  Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. , 2005, Journal of Medicinal Chemistry.

[40]  S. Opella,et al.  Structure of the Chemokine Receptor CXCR1 in Phospholipid Bilayers , 2012, Nature.

[41]  O. Berger,et al.  Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.

[42]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[43]  A. Amadei,et al.  On the convergence of the conformational coordinates basis set obtained by the essential dynamics analysis of proteins' molecular dynamics simulations , 1999, Proteins.

[44]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[45]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[46]  Q. Dong,et al.  Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity‐related insulin resistance , 2001, Diabetes, obesity & metabolism.

[47]  Angus N R Nedderman,et al.  Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. , 2008, British journal of clinical pharmacology.

[48]  M. Baaden,et al.  Conformational sampling and dynamics of membrane proteins from 10‐nanosecond computer simulations , 2004, Proteins.

[49]  W. Goddard,et al.  Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor , 2011, Proteins.

[50]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[51]  Jonathan S. Mason,et al.  Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.

[52]  Francesca Fanelli,et al.  Contributions of intracellular loops 2 and 3 of the lutropin receptor in Gs coupling. , 2008, Molecular endocrinology.

[53]  S. Iwata,et al.  G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.

[54]  Albert C. Pan,et al.  Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.

[55]  R. Paschke,et al.  Role of the third intracellular loop for the activation of gonadotropin receptors. , 1999, Molecular endocrinology.

[56]  R. Hauser,et al.  Adenosine A2A Receptor Antagonists for Parkinson’s Disease , 2005, Drugs & aging.

[57]  P. Fishman,et al.  Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. , 2005, The Journal of rheumatology.

[58]  Michael Wiese,et al.  Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243 , 2006, J. Comput. Aided Mol. Des..

[59]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[60]  William J. Allen,et al.  Practical Considerations for Building GROMOS-Compatible Small-Molecule Topologies , 2010, J. Chem. Inf. Model..

[61]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[62]  K. Schulten,et al.  Principal Component Analysis and Long Time Protein Dynamics , 1996 .

[63]  Tod D Romo,et al.  Block Covariance Overlap Method and Convergence in Molecular Dynamics Simulation. , 2011, Journal of chemical theory and computation.

[64]  B M Pettitt,et al.  A sampling problem in molecular dynamics simulations of macromolecules. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[66]  P. Biggin,et al.  Molecular Dynamics Simulations of the Ligand-binding Domain of an N-Methyl-d-aspartate Receptor* , 2006, Journal of Biological Chemistry.

[67]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[68]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[69]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[70]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[71]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[72]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[73]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[74]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[75]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[76]  Oliver P. Ernst,et al.  Crystal Structure of Native Opsin: the G Protein-Coupled Receptor Rhodopsin in its Ligand-free State , 2008 .

[77]  Albert C. Pan,et al.  Activation mechanism of the β2-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.

[78]  Cheng Zhang,et al.  High-resolution Crystal Structure of Human Protease-activated Receptor 1 Bound to the Antagonist Vorapaxar Hhs Public Access , 2022 .

[79]  J. Konopka,et al.  Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Ursula Rothlisberger,et al.  Early steps of the intramolecular signal transduction in rhodopsin explored by molecular dynamics simulations. , 2002, Biochemistry.

[81]  M. Mortrud,et al.  The G protein-coupled receptor repertoires of human and mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[83]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[84]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[85]  Bernhard Pfeiffer,et al.  Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. , 2005, Chemical reviews.

[86]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[87]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[88]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[89]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[90]  M. Freissmuth,et al.  Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. , 2010, Current pharmaceutical design.

[91]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[92]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[93]  C. Dourish,et al.  Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease , 2003, Neurology.

[94]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[95]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[96]  P. Biggin,et al.  Molecular dynamics simulations of the ligand-binding domain of the ionotropic glutamate receptor GluR2. , 2002, Biophysical journal.

[97]  J. Shiloach,et al.  Structure of the agonist-bound neurotensin receptor , 2012, Nature.